Leukogene Therapeutics Secures Strategic Funding From SCRA and SC Launch

Why It Matters

The infusion of public‑sector capital bolsters Leukogene’s ability to advance its pipeline, potentially accelerating the delivery of novel treatments for hard‑to‑treat cancers and enhancing South Carolina’s biotech ecosystem.

Deal Summary

Leukogene Therapeutics, a biopharmaceutical firm focused on next‑generation cancer therapies, announced it has received strategic funding from the South Carolina Research Authority and its affiliate SC Launch Inc. The financing, disclosed on November 12, 2025, aims to accelerate the company's development pipeline.